Jay R. Luly, President and CEO at ENANTA PHARMACEUTICALS INC (ENTA), sold 15,000 shares at $34.88 ($501K) on 2015-03-09, disclosed to the SEC on 2015-03-10.
Scheduled sale ($501k) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $33.13 | 11,300 | $374K | 74.8% |
| 2 | $34.07 | 3,600 | $123K | 24.5% |
| 3 | $34.88 | 100 | $3K | 0.7% |
| Total | $33.37 avg | 15,000 | $501K | 100% |
| Filing → |
| ENTA | SELL | 2024-12-10 | $41K | — | Filing → |
| ENTA | SELL | 2023-12-06 | $139K | — | Filing → |
| ENTA | SELL | 2023-03-14 | $2.5M | — | Filing → |